Replimune Group Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Replimune Group Inc. |
| Ticker: | Ticker: REPL |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
On July 28, 2026, the FDA released briefing documents regarding the Company’s lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents revealed the FDA has deemed the single-armed mid-stage study submitted by Replimune to support the drug’s approval as “non interpretable.” FDA reviewers stated the assessment used in the study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results.”
On this news, Replimune’s stock price fell $3.28, or approximately 38%, to close at $5.35 on July 28, 2026.
On this news, Replimune’s stock price fell $3.28, or approximately 38%, to close at $5.35 on July 28, 2026.